Literature DB >> 12739737

GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome.

F Orio1, S Palomba, A Colao, T Russo, C Dentico, L Tauchmanovà, S Savastano, C Nappi, C Sultan, F Zullo, G Lombardi.   

Abstract

Few and unclear data are available in the literature about the relationship between impairment of GH/IGF-I axis and polycystic ovary syndrome (PCOS). This study was aimed to evaluate the basal GH and IGF- levels, and GH release after challenge test in obese and overweight women with PCOS. Thirty patients with PCOS and other 30 healthy women matched for age, body mass index (BMI) and waist-hip ratio (WHR) were studied. Serum follicle-stimulating hormone (FSH), LH, PRL, E2, P, 17OH-progesterone (17OH-P), total T, delta4, DHEA-S, SHBG, GH and IGF-I levels were evaluated in each subject. A GHRH plus arginine challenge test was performed in all subjects. After provocative test, in PCOS and control women the GH levels were significantly (p<0.05) higher in comparison to basal values from 30 min to 120 min. At the same times, a significant (p<0.05) difference was observed between women with PCOS in comparison to healthy women. The mean peak value of GH resulted significantly (p<0.05) lower in PCOS women in comparison to healthy women. The total GH response (area under curve, AUC) to GHRH plus arginine test resulted significantly (p<0.05) lower in PCOS than in healthy women. These findings were statistically significant (p<0.05) also considering the distinction in obese and overweight women. The AUC for GH secretion was significantly lower (p<0.05) in obese in comparison to overweight subjects in the control group, whereas no significant difference was detected between obese and overweight women in the PCOS group. In conclusion, in PCOS women there is a BMI-independent alteration of the GH levels. Further investigations will be necessary to establish the real cause of these data.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12739737     DOI: 10.1007/BF03345138

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  41 in total

1.  Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults.

Authors:  G Aimaretti; G Corneli; P Razzore; S Bellone; C Baffoni; E Arvat; F Camanni; E Ghigo
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

2.  Insulin and the polycystic ovary syndrome.

Authors:  R D Utiger
Journal:  N Engl J Med       Date:  1996-08-29       Impact factor: 91.245

Review 3.  The potential relevance of growth hormone to female reproductive physiology and pathophysiology.

Authors:  E Katz; E Ricciarelli; E Y Adashi
Journal:  Fertil Steril       Date:  1993-01       Impact factor: 7.329

Review 4.  Polycystic ovary syndrome.

Authors:  S Franks
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

Review 5.  Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults.

Authors:  E Ghigo; G Aimaretti; E Arvat; F Camanni
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

6.  Paradoxical growth hormone response following thyroid-stimulating hormone administration in the polycystic ovary syndrome.

Authors:  M L Anapliotou; K Syrigos; G Panayiotakopoulos; A Kalos; M L Batrinos
Journal:  Horm Res       Date:  1989

Review 7.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

Authors:  A Dunaif
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

8.  Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism.

Authors:  D Apter; T Bützow; G A Laughlin; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1995-10       Impact factor: 5.958

9.  Twenty-four-hour serum growth hormone, insulin, C-peptide and blood glucose profiles and serum insulin-like growth factor-I concentrations in women with polycystic ovaries.

Authors:  G M Prelević; M I Wurzburger; L Balint-Perić; J Ginsburg
Journal:  Horm Res       Date:  1992

10.  Growth hormone response to L-dopa and pyridostigmine in women with polycystic ovarian syndrome.

Authors:  E J Lee; B S Lee; H C Lee; K H Park; C H Song; K B Huh
Journal:  Fertil Steril       Date:  1993-07       Impact factor: 7.329

View more
  3 in total

1.  Growth hormone secretion in primary and secondary hyperparathyroidism.

Authors:  E Cecconi; M Gasperi; M Genovesi; F Bogazzi; L Grasso; M Procopio; C Marcocci; A Pinchera; L Bartalena; E Martino
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

2.  Effects of ghrelin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome.

Authors:  A Fusco; A Bianchi; A Mancini; D Milardi; A Giampietro; V Cimino; T Porcelli; D Romualdi; M Guido; A Lanzone; A Pontecorvi; L De Marinis
Journal:  J Endocrinol Invest       Date:  2007-12       Impact factor: 4.256

3.  Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome.

Authors:  Jessica K Devin; Hui Nian; Jorge E Celedonio; Patricia Wright; Nancy J Brown
Journal:  J Clin Endocrinol Metab       Date:  2020-01-01       Impact factor: 5.958

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.